Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
MWN-AI** Summary
Adlai Nortye Ltd. (NASDAQ: ANL), a biotechnology company specializing in innovative cancer therapies, has marked a significant milestone with the dosing of the first patient in its global Phase 1 clinical trial of AN9025, an oral pan-RAS (ON) inhibitor. This trial, which commenced in early February 2026, is designed to assess the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of AN9025 in patients suffering from advanced or metastatic solid tumors with RAS mutations. The multicenter, open-label study is being conducted in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd., allowing Adlai Nortye to maintain rights to AN9025 outside of China, where ASK Pharm holds interests.
Dr. Archie Tse, Adlai Nortye's Head of Research and Development, described this event as a significant advance in their clinical strategy, which aims to explore the potential of AN9025 across a range of solid tumors affected by RAS mutations. The data generated from this trial is expected to provide crucial insights into the drug's capabilities in tackling RAS-driven cancers, which include pancreatic, lung, and colorectal adenocarcinomas.
AN9025's preclinical studies have shown promising results, demonstrating potent and durable efficacy while promising to outperform benchmarks in its drug class. Adlai Nortye, leveraging a dual research and development presence in the U.S. and China, is also focused on developing next-generation cancer immunotherapies through other candidates in its pipeline.
This trial and Adlai Nortye's strategic initiatives reflect the company’s commitment to advancing innovative cancer treatments and establishing itself as a leader in the Oncology biopharmaceutical sector.
MWN-AI** Analysis
Adlai Nortye Ltd. (NASDAQ: ANL) has recently achieved a significant milestone by enrolling the first patient in its global Phase 1 trial for AN9025, a pan-RAS (ON) inhibitor targeting RAS mutations in solid tumors. This announcement is pivotal for investors, as it marks a key step in evaluating AN9025's safety and potential effectiveness against difficult-to-treat cancers, including pancreatic and lung adenocarcinomas.
Investors should be encouraged by the importance of RAS mutations in cancer, as these alterations are implicated in various solid tumors and are a target of increasing focus by oncology researchers. Given its promising preclinical results, which indicate that AN9025 may outperform existing RAS inhibitors, there is a potential for substantial market demand if the drug advances successfully through clinical trials.
Adlai Nortye’s strategy appears robust, with a dual R&D presence in the U.S. and China and an emphasis on innovative cancer therapies. Their collaboration with Jiangsu Aosaikang Pharmaceutical broadens the reach of their product in the lucrative Asian markets while maintaining their ex-China rights, which bodes well for international revenue growth.
However, investors should remain mindful of the inherent risks associated with clinical-stage biotech firms, particularly in the realm of drug development where outcomes can be unpredictable. The company's future relies heavily on the successful progression of clinical trials and subsequent regulatory approvals. The broader market sentiments around biotech can also influence stock performance, especially during periods of heightened volatility associated with trial results and FDA announcements.
For those considering investing in Adlai Nortye, it may be wise to watch for updates on trial progress and early data releases, as these could substantially impact share prices. Diversification within the biotech sector may mitigate some risks associated with this high-stakes investment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in early February in its ongoing Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor.
The Phase 1 study is a first-in-human, multicenter, open-label trial designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations. This trial is being conducted by Adlai Nortye in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (“ASK Pharm”) as a multi-regional clinical trial (“MRCT”) pursuant to a license agreement, under which Adlai Nortye retains ex-China rights to AN9025, while ASK Pharm holds rights in mainland China, Hong Kong and Macao.
“Dosing the first U.S. patient with AN9025, our wholly in-house discovered, oral pan-RAS(ON) inhibitor with best-in-class potential, is a significant milestone,” said Dr. Archie Tse, Head of Research and Development at Adlai Nortye. “This achievement advances our clinical strategy to evaluate AN9025 across multiple RAS-mutant solid tumors. We look forward to efficiently progressing its global clinical development and generating meaningful data to support its future advancement.”
About AN9025
AN9025 is an oral small molecule pan-RAS(ON) inhibitor with best-in-class potential, designed to target a broad spectrum of RAS mutations across various tumor types. Preclinical studies have demonstrated that AN9025 effectively inhibits RAS-mutant cancers with potent and durable efficacy, including pancreatic, lung, and colorectal adenocarcinomas, and shows comparable or superior results relative to a benchmark agent of the same class.
About Adlai Nortye
Adlai Nortye (NASDAQ: ANL) is a global clinical-stage company at the forefront of discovering and developing innovative cancer therapies. Leveraging our dual R&D presence in the U.S. and China, we are building a robust pipeline of drug candidates focused on two key areas where we believe we can make a significant difference. (1) Next-generation cancer immunotherapies: our candidates, AN8025 (a tri-functional fusion protein of ?PD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways. (2) RAS-targeting therapies: we are tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors.
Forward-Looking Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.
The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company’s preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company’s therapeutic candidates; the Company’s ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this announcement and in the attachments is as of the date of this announcement, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Company contact:
Investor Relations
Email: ir@adlainortye.com
FAQ**
How is Adlai Nortye Ltd. ANL leveraging its dual R&D presence in Singapore and the U.S. to enhance the clinical development of AN9025 in treating RAS-mutant solid tumors?
What specific regulatory challenges might Adlai Nortye Ltd. ANL face in both Singapore and North Brunswick, NJ, as the Phase 1 trial for AN90progresses?
How does the growing biotech ecosystem in Hangzhou, China, benefit Adlai Nortye Ltd. ANL's collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. in the clinical trial of AN9025?
In what ways might the results of the AN9025 clinical trial impact cancer treatment strategies in Singapore and North Brunswick, NJ, given the focus on RAS-driven cancers by Adlai Nortye Ltd. ANL?
**MWN-AI FAQ is based on asking OpenAI questions about Adlai Nortye Ltd. (NASDAQ: ANL).
NASDAQ: ANL
ANL Trading
3.8% G/L:
$9.16 Last:
106,850 Volume:
$8.77 Open:
